Form 4: Omada Health Director Adam Stavisky Receives Equity Grant of 9,736 Restricted Stock Units

Omada Health, Inc. Director Adam Stavisky was granted 9,736 restricted stock units (RSUs) on June 5, 2025, as part of his compensation.

Summary

• Adam Stavisky, a Director of Omada Health, Inc. (OMDA), acquired 9,736 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 5, 2025, with an acquisition price of $0 per share, indicating a grant rather than a purchase.
• These RSUs will fully vest on the first anniversary of the grant date, specifically June 5, 2026, at which point each RSU will convert into one share of Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates standard corporate governance practice of aligning director interests with shareholders through equity compensation. It's not a major catalyst but a routine positive.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Adam Stavisky aligns his interests with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for retaining and incentivizing key personnel and directors.

Risks

• The value of the granted RSUs is subject to market fluctuations of Omada Health's common stock.
• The RSUs are subject to a vesting schedule, meaning the recipient must remain with the company until June 5, 2026, to fully realize the benefit; otherwise, unvested units may be forfeited.

Future Outlook

The 9,736 Restricted Stock Units granted to Director Adam Stavisky are scheduled to fully vest on June 5, 2026, converting into shares of Omada Health's Common Stock.

Management Comments

• The transaction reflects a standard equity compensation grant to a director, aligning management's long-term interests with shareholder value creation.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a common form of equity compensation across various industries, particularly in technology and healthcare sectors, used to attract, retain, and incentivize board members by linking their compensation to the company's long-term performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a widely accepted practice across publicly traded companies, including those in the healthcare technology sector like Omada Health.
• The vesting schedule, typically over one to several years, is standard for such grants, ensuring long-term alignment.
• While the specific number of units granted varies by company size, director role, and overall compensation philosophy, this type of equity award is comparable to practices seen at companies like Teladoc Health (TDOC) or Livongo Health (LVGO, prior to acquisition), which also utilize equity for executive and director incentives.

Related Party Transactions

• The acquisition of 9,736 Restricted Stock Units (RSUs) by Adam Stavisky, a Director of Omada Health, Inc., constitutes a related party transaction as it involves an insider receiving equity compensation from the company.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates.
• Employees: While not directly impacting employees, such grants are part of a broader compensation strategy that can influence overall company culture and retention of key talent.

Next Steps

• The 9,736 Restricted Stock Units (RSUs) granted to Adam Stavisky are expected to vest on June 5, 2026, at which point they will convert into shares of Omada Health Common Stock.

Key Dates

Keywords

Omada Health, OMDA, Form 4, SEC Filing, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Director Compensation, Stock Grant, Corporate Governance